Diagnosing dementia in the clinical setting: can amyloid PET provide additional value over cerebrospinal fluid?

Manuscript Number: 

16-0302R2

Author(s): 
Anna Barnes, Jamshed Bomanji, John Dickson, Nick C. Fox, Irfan Kayani, Michael P. Lunn, Catherine J. Mummery, Ross W. Paterson, Martin N. Rossor, Jonathan M. Schott, Jason D. Warren, Philip S.J. Weston, Henrik Zetterberg

Disclosures

Anna Barnes

  • Nothing to Disclose

Jamshed Bomanji

  • Nothing to Disclose

John Dickson

  • Nothing to Disclose

Nick C. Fox

  • Consulting Fees:
    I provide consultancy services to Eli Lilly, Novartis, Sanofi, Roche, GSK, and Biogen - all payments were to UCL Institute of Neurology.

Irfan Kayani

  • Nothing to Disclose

Michael P. Lunn

  • Consulting Fees:
    I have received ad hoc consulting fees from CSL Behring, Baxalta, Novartis and Grifols for single advisory board attendances in relation to products used to treat inflammatory neuropathies

Catherine J. Mummery

  • Nothing to Disclose

Ross W. Paterson

  • Nothing to Disclose

Martin N. Rossor

  • Consulting Fees:
    Membership of SMC for Servier AD trial Fees paid to university

Jonathan M. Schott

  • Consulting Fees:
    I have consulted for Roche Pharmaceuticals and Eli Lilly.
    Lecture Fees:
    I have received lecture fees from Eli Lilly
    Patents/Royalties
    I serve on a Data Safety Monitoring Committee for Axon Neuroscience SE
    Grants
    • Agency: 
      AVID Radiopharmaceuticals
      Dates: 
      2012-14

Jason D. Warren

  • Nothing to Disclose

Philip S.J. Weston

  • Nothing to Disclose

Henrik Zetterberg

  • Nothing to Disclose